Erasca (ERAS) Other Non-Current Assets (2020 - 2026)
Erasca posted quarterly Other Non-Current Assets of $1.4 million for Q1 2026, down 44.7% year-on-year from $2.6 million in Q1 2025, and up 254.41% on a QoQ basis from $408000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Other Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 44.7% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 44.7% YoY), and the FY2025 full-year result was $408000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.4 million, up from $408000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.4 million in Q3 2023 and bottomed at $408000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $408000.0 (2022), against an average of $1.3 million.
- The widest annual swing landed in 2023, when Other Non-Current Assets surged 975.49%; it then slumped 90.69% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $408000.0 in 2022, then jumped by 974.26% to $4.4 million in 2023, then plunged by 90.69% to $408000.0 in 2024, then changed by 0.0% to $408000.0 in 2025, then surged by 254.41% to $1.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.4 million (Q1 2026), $408000.0 (Q4 2025), and $408000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 408,000.00 |
| Sep 30, 2025 | 408,000.00 |
| Jun 30, 2025 | 408,000.00 |
| Mar 31, 2025 | 2.62 Mn |
| Dec 31, 2024 | 408,000.00 |
| Sep 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 408,000.00 |
| Mar 31, 2024 | 408,000.00 |
| Dec 31, 2023 | 4.38 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 408,000.00 |
| Mar 31, 2023 | 408,000.00 |
| Dec 31, 2022 | 408,000.00 |
| Sep 30, 2022 | 408,000.00 |
| Jun 30, 2022 | 408,000.00 |
| Mar 31, 2022 | 408,000.00 |
| Dec 31, 2021 | 2.91 Mn |
| Sep 30, 2021 | 408,000.00 |
| Jun 30, 2021 | 408,000.00 |
| Mar 31, 2021 | 408,000.00 |
| Dec 31, 2020 | 312,000.00 |
| Sep 30, 2020 | 408,000.00 |